Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Malignant Lymphoma

  Free Subscription


Articles published in Blood

Retrieve available abstracts of 332 articles:
HTML format



Single Articles


    June 2022
  1. PAREKH A, Keller FG, McCarten KM, Kessel S, et al
    Targeted Radiotherapy for Early-Stage Low-Risk Pediatric Hodgkin Lymphoma Slow Early Responders: A COG AHOD0431 Analysis.
    Blood. 2022 Jun 28. pii: 485708. doi: 10.1182/blood.2022016098.
    PubMed     Abstract available


  2. PINDZOLA GM, Razzaghi R, Tavory RN, Nguyen HT, et al
    Aberrant expansion of spontaneous splenic germinal centers induced by hallmark genetic lesions of aggressive lymphoma.
    Blood. 2022 Jun 27. pii: 485703. doi: 10.1182/blood.2022015926.
    PubMed     Abstract available


  3. FERRERO S, Grimaldi D, Genuardi E, Drandi D, et al
    Punctual and kinetic MRD analysis from the Fondazione Italiana Linfomi MCL0208 phase III trial in mantle cell lymphoma.
    Blood. 2022 Jun 23. pii: 485688. doi: 10.1182/blood.2021014270.
    PubMed     Abstract available


  4. JOHNSON PWM
    Smart salvage treatment for Hodgkin lymphoma.
    Blood. 2022;139:3563-3564.
    PubMed    


  5. IZQUIERDO E, Vorholt D, Blakemore S, Sackey B, et al
    Extracellular vesicles and PD-L1 suppress macrophages, inducing therapy resistance in TP53-deficient B-cell malignancies.
    Blood. 2022;139:3617-3629.
    PubMed     Abstract available


  6. BACKER K, Wang HY
    Florid reactive follicular hyperplasia with exuberant HHV8 infection.
    Blood. 2022;139:3558.
    PubMed    


  7. KAMBHAMPATI S, Saumoy M, Schneider Y, Pak S, et al
    Cost Effectiveness of Polatuzumab Vedotin Combined with Chemoimmunotherapy in Untreated Diffuse Large B-cell Lymphoma.
    Blood. 2022 Jun 14. pii: 485545. doi: 10.1182/blood.2022016624.
    PubMed     Abstract available


  8. GHIONE P, Palomba ML, Patel A, Bobillo S, et al
    Comparative effectiveness of ZUMA-5 (axi-cel) vs SCHOLAR-5 external control in relapsed/refractory follicular lymphoma.
    Blood. 2022 Jun 9. pii: 485518. doi: 10.1182/blood.2021014375.
    PubMed     Abstract available


  9. PETERSON JM, Lyapichev KA
    Extranodal natural killer/T-cell lymphoma of the palate.
    Blood. 2022;139:3450.
    PubMed    


  10. FERNANDEZ-SEVILLA LM, Valencia J, Ortiz-Sanchez P, Fraile-Ramos A, et al
    High BMP4 expression in low/intermediate risk BCP-ALL identifies children with poor outcomes.
    Blood. 2022;139:3303-3313.
    PubMed     Abstract available


    May 2022
  11. HAMNVAG HM, Velankar M
    Hemophagocytic lymphohistiocytosis with multiple possible etiologies including rare primary bone marrow lymphoma.
    Blood. 2022;139:3226.
    PubMed    


  12. KAMDAR M
    A cauldron of choices.
    Blood. 2022;139:3103-3104.
    PubMed    


  13. CERHAN JR
    A (modifiable) way to better Hodgkin lymphoma survivorship?
    Blood. 2022;139:3004-3005.
    PubMed    


  14. CALABRETTA E, Hamadani M, Carlo-Stella C
    THE ANTIBODY-DRUG CONJUGATE LONCASTUXIMAB TESIRINE FOR THE TREATMENT OF DIFFUSE LARGE B-CELL LYMPHOMA.
    Blood. 2022 May 17. pii: 485279. doi: 10.1182/blood.2021014663.
    PubMed     Abstract available


  15. ALI A, Goy A, Dunleavy K
    CAR T-cell Therapy in Highly-Aggressive B-Cell Lymphoma: Emerging Biological and Clinical Insights.
    Blood. 2022 May 13. pii: 485238. doi: 10.1182/blood.2022016226.
    PubMed     Abstract available


  16. ATANACKOVIC D, Luetkens T, Omili D, Iraguha T, et al
    Vaccine-induced T cells against Sars-Cov-2 and its Omicron variant in B cell-depleted lymphoma patients after CART.
    Blood. 2022 May 10. pii: 485211. doi: 10.1182/blood.2022016175.
    PubMed    


  17. CHERNG HJ, Sun R, Sugg B, Irwin R, et al
    Risk assessment with low pass whole genome sequencing of cell free DNA before CD19 CAR T-cells for large B-cell lymphoma.
    Blood. 2022 May 5. pii: 485178. doi: 10.1182/blood.2022015601.
    PubMed     Abstract available


  18. NAKAMURA A, Grossman S, Song K, Xega K, et al
    The SUMOylation inhibitor subasumstat potentiates rituximab activity by IFN1-dependent macrophage and NK cell stimulation.
    Blood. 2022;139:2770-2781.
    PubMed     Abstract available


    April 2022
  19. TADROS S, Jaffe ES
    A novel case of gamma-delta T-cell lymphoma expressing CD4, recapitulating a stage of gamma-delta T-cell development.
    Blood. 2022;139:2725.
    PubMed    



  20. Lowe EJ, Reilly AF, Lim MS, et al. Brentuximab vedotin in combination with chemotherapy for pediatric patients with ALK+ ALCL: results of COG trial ANHL12P1. Blood. 2021;137(26):3595-3603.
    Blood. 2022;139:2726.
    PubMed    


  21. SONIGO G, Bozonnat A, Dumont M, Thonnart N, et al
    Involvement of the CD39/CD73/adenosine pathway in T-cell proliferation and NK cell-mediated antibody-dependent cell cytotoxicity in Sezary syndrome.
    Blood. 2022;139:2712-2716.
    PubMed    


  22. JAIN MD, Ziccheddu B, Coughlin CA, Faramand RG, et al
    Whole-genome sequencing reveals complex genomic features underlying anti-CD19 CAR T-cell treatment failures in lymphoma.
    Blood. 2022 Apr 27. pii: 485092. doi: 10.1182/blood.2021015008.
    PubMed     Abstract available


  23. PORTELL CA
    CNS prophylaxis in DLBCL: first do no harm.
    Blood. 2022;139:2420-2421.
    PubMed    


  24. WILSON MR, Eyre TA, Kirkwood AA, Wong Doo N, et al
    Timing of high-dose methotrexate CNS prophylaxis in DLBCL: a multicenter international analysis of 1384 patients.
    Blood. 2022;139:2499-2511.
    PubMed     Abstract available


  25. BEYGI S, Duran GE, Fernandez-Pol S, Rook AH, et al
    Resistance to mogamulizumab is associated with loss of CCR4 in Cutaneous T-cell Lymphoma.
    Blood. 2022 Apr 18. pii: 484969. doi: 10.1182/blood.2021014468.
    PubMed     Abstract available


  26. CHONG EA, Schuster SJ
    No CNS sanctuary for lymphoma from CAR T.
    Blood. 2022;139:2261-2263.
    PubMed    


  27. BATLEVI CL
    Chemotherapy-free regimens in frontline follicular lymphoma.
    Blood. 2022;139:2263-2264.
    PubMed    


  28. QUINTANILLA-MARTINEZ L, Fend F
    Turning up the heat on salivary gland MALT lymphoma.
    Blood. 2022;139:2094-2096.
    PubMed    


    March 2022
  29. LIANG HC, Elenitoba-Johnson KSJ
    Targeting IMiD-resistant T-cell lymphoma.
    Blood. 2022;139:1932-1933.
    PubMed    


  30. WU W, Nelson GM, Koch R, Donovan KA, et al
    Overcoming IMiD resistance in T-cell lymphomas through potent degradation of ZFP91 and IKZF1.
    Blood. 2022;139:2024-2037.
    PubMed     Abstract available


  31. QI Y, Zhao M, Hu Y, Wang Y, et al
    Efficacy and safety of CD19-specific CAR T-cell-based therapy in B-cell acute lymphoblastic leukemia patients with CNSL.
    Blood. 2022 Mar 25. pii: 484499. doi: 10.1182/blood.2021013733.
    PubMed     Abstract available


  32. KURTZ DM
    The many facets of liquid biopsies in lymphoma.
    Blood. 2022;139:1780-1781.
    PubMed    


  33. DE MASSON A, Darbord D, Dobos G, Boisson M, et al
    Macrophage-derived CXCL9 and CXCL11, T-cell skin homing, and disease control in mogamulizumab-treated CTCL patients.
    Blood. 2022;139:1820-1832.
    PubMed     Abstract available


  34. SIDDIQI T, Soumerai JD, Dorritie KA, Stephens DM, et al
    Phase 1 TRANSCEND CLL 004 study of lisocabtagene maraleucel in patients with relapsed/refractory CLL or SLL.
    Blood. 2022;139:1794-1806.
    PubMed     Abstract available


  35. MEI MG, Lee HJ, Palmer J, Chen RW, et al
    Response-adapted anti-PD1 based salvage therapy for Hodgkin lymphoma with nivolumab +/- ICE (NICE).
    Blood. 2022 Mar 22. pii: 484451. doi: 10.1182/blood.2022015423.
    PubMed     Abstract available


  36. BETHGE WA, Martus P, Schmitt M, Holtick U, et al
    GLA/DRST real-world outcome analysis of CAR-T cell therapies for large B-cell lymphoma in Germany.
    Blood. 2022 Mar 22. pii: 484450. doi: 10.1182/blood.2021015209.
    PubMed     Abstract available


  37. SONG Y, Zhou K, Zou DH, Zhou J, et al
    Zanubrutinib in relapsed/refractory mantle cell lymphoma: long-term efficacy and safety results from a phase 2 study.
    Blood. 2022 Mar 18. pii: 484435. doi: 10.1182/blood.2021014162.
    PubMed     Abstract available


  38. LEONARD JP
    POD24 in follicular lymphoma: time to be "wise".
    Blood. 2022;139:1609-1610.
    PubMed    



  39. Bobillo S, Joffe E, Lavery JA, et al. Clinical characteristics and outcomes of extranodal stage I diffuse large B-cell lymphoma in the rituximab era. Blood. 2021;137(1):39-48.
    Blood. 2022;139:1772.
    PubMed    


  40. AYPAR U, Ewalt MD
    A very Burkitt-like case of Burkitt-like lymphoma with 11q aberration.
    Blood. 2022;139:1771.
    PubMed    


  41. CASULO C, Dixon JG, Le-Rademacher J, Hoster E, et al
    Validation of POD24 as a robust early clinical end point of poor survival in FL from 5225 patients on 13 clinical trials.
    Blood. 2022;139:1684-1693.
    PubMed     Abstract available


  42. PORPACZY E, Jager U
    How I manage autoimmune cytopenias in patients with lymphoid cancer.
    Blood. 2022;139:1479-1488.
    PubMed     Abstract available


  43. NAYAK L, Batchelor TT
    How I treat neurologic complications in patients with lymphoid cancer.
    Blood. 2022;139:1469-1478.
    PubMed     Abstract available


  44. WESTIN JR, Sehn L
    CAR T-cells as a second-line therapy of large B-cell lymphoma: A paradigm shift?
    Blood. 2022 Mar 3. pii: 484263. doi: 10.1182/blood.2022015789.
    PubMed     Abstract available


  45. LULLA PD
    CAR T cells and autologous transplantation can coexist for DLBCL.
    Blood. 2022;139:1266-1267.
    PubMed    


  46. SHADMAN M, Pasquini M, Ahn KW, Chen Y, et al
    Autologous transplant vs chimeric antigen receptor T-cell therapy for relapsed DLBCL in partial remission.
    Blood. 2022;139:1330-1339.
    PubMed     Abstract available


    February 2022

  47. Panea RI, Love CL, Shingleton JR, et al. The whole-genome landscape of Burkitt lymphoma subtypes. Blood. 2019;134(19):1598-1607.
    Blood. 2022;139:1256.
    PubMed    


  48. MARTIN P, Bartlett NL, Chavez JC, Reagan JL, et al
    Phase 1 study of oral azacitidine (CC-486) plus R-CHOP in previously untreated intermediate- to high-risk DLBCL.
    Blood. 2022;139:1147-1159.
    PubMed     Abstract available


  49. SHAH NN, Harrington AM
    Hemophagocytosis in cerebrospinal fluid after CAR T-cell therapy.
    Blood. 2022;139:1116.
    PubMed    


  50. CHONG EA, Alanio C, Svoboda J, Nasta SD, et al
    Pembrolizumab for B-cell lymphomas relapsing after or refractory to CD19-directed CAR T-cell therapy.
    Blood. 2022;139:1026-1038.
    PubMed     Abstract available


  51. FRIGAULT MJ, Dietrich J, Gallagher KME, Roschewski MJ, et al
    Safety and Efficacy of Tisagenlecleucel in Primary CNS Lymphoma: A phase I/II clinical trial.
    Blood. 2022 Feb 15. pii: 484042. doi: 10.1182/blood.2021014738.
    PubMed     Abstract available


  52. KIM DH, Vega F
    Relapsed classic Hodgkin lymphoma with decreased CD30 expression after brentuximab and anti-CD30 CAR-T therapies.
    Blood. 2022;139:951.
    PubMed    


  53. CAO X, Wang Y, Zhang W, Zhong X, et al
    Targeting macrophages for enhancing CD47 blockade-elicited lymphoma clearance and overcoming tumor-induced suppression.
    Blood. 2022 Feb 8. pii: 483887. doi: 10.1182/blood.2021013901.
    PubMed     Abstract available


  54. DEAGLIO S, Vaisitti T
    A new taxonomy for splenic marginal zone lymphoma.
    Blood. 2022;139:644-645.
    PubMed    


  55. YU YT, Chang KC
    Burkitt-like lymphoma with 11q aberrations: a highly apoptotic and high-grade lymphoma.
    Blood. 2022;139:797.
    PubMed    


  56. DAVIDS MS, Rogers KA, Tyekucheva S, Wang Z, et al
    Venetoclax plus dose-adjusted R-EPOCH for Richter syndrome.
    Blood. 2022;139:686-689.
    PubMed     Abstract available


    January 2022
  57. KLEIN U
    Metabolic path toward TCF3 inactivation in Burkitt lymphoma.
    Blood. 2022;139:475-476.
    PubMed    


  58. TARIQ H, Zahra U
    Fibrin-associated diffuse large B-cell lymphoma with aberrant CD4 expression.
    Blood. 2022;139:635.
    PubMed    


  59. WILKE AC, Doebele C, Zindel A, Lee KS, et al
    SHMT2 inhibition disrupts the TCF3 transcriptional survival program in Burkitt lymphoma.
    Blood. 2022;139:538-553.
    PubMed     Abstract available


  60. AARAKAKI H, Karube K
    Small-cell pattern of DUSP22 rearranged ALK-negative anaplastic large-cell lymphoma with leukemic phase.
    Blood. 2022;139:465.
    PubMed    


  61. SCHMITZ N, Frontzek F
    CNS prophylaxis in DLBCL: time to say goodbye?
    Blood. 2022;139:315-317.
    PubMed    


  62. ORELLANA-NOIA VM, Reed DR, McCook AA, Sen JM, et al
    Single-route CNS prophylaxis for aggressive non-Hodgkin lymphomas: real-world outcomes from 21 US academic institutions.
    Blood. 2022;139:413-423.
    PubMed     Abstract available


  63. COTTEREAU AS
    PET imaging: back in the game for gastric EMZL?
    Blood. 2022;139:154-155.
    PubMed    


  64. FUJIHARA M, Sakata R, Yoshida N, Ozasa K, et al
    Incidence of lymphoid neoplasms among atomic bomb survivors by histological subtype, 1950 to 1994.
    Blood. 2022;139:217-227.
    PubMed     Abstract available


  65. SHEN Y, Zhou J, Nie K, Cheng S, et al
    Oncogenic role of the SOX9-DHCR24-cholesterol biosynthesis axis in IGH-BCL2+ diffuse large B-cell lymphomas.
    Blood. 2022;139:73-86.
    PubMed     Abstract available


  66. ANDRADES DELGADO A, Alvarez-Perez JC, Patino-Mercau JR, Cuadros M, et al
    Recurrent splice site mutations affect key diffuse large B-cell lymphoma genes.
    Blood. 2022 Jan 5. pii: 483332. doi: 10.1182/blood.2021011708.
    PubMed    


    December 2021
  67. MOSKOWITZ AJ, Ghione P, Jacobsen E, Ruan J, et al
    A phase 2 biomarker-driven study of ruxolitinib demonstrates effectiveness of JAK/STAT targeting in T-cell lymphomas.
    Blood. 2021;138:2828-2837.
    PubMed     Abstract available


  68. LIU H, Hu S
    EBV+ ALK+ large B-cell lymphoma.
    Blood. 2021;138:2741.
    PubMed    


  69. BACHY E, Houot R, Feugier P, Bouabdallah K, et al
    Obinutuzumab plus lenalidomide (GALEN) in advanced, previously untreated follicular lymphoma in need of systemic therapy.
    Blood. 2021 Dec 22. pii: 483234. doi: 10.1182/blood.2021013526.
    PubMed     Abstract available


  70. HAWKES EA, Barraclough A, Sehn LH
    Limited-stage Diffuse Large B-cell Lymphoma.
    Blood. 2021 Dec 21. pii: 483215. doi: 10.1182/blood.2021013998.
    PubMed     Abstract available


  71. MERIRANTA L, Alkodsi A, Pasanen A, Lepisto M, et al
    Molecular features encoded in the ctDNA reveal heterogeneity and predict outcome in high-risk aggressive B-cell lymphoma.
    Blood. 2021 Dec 21. pii: 483214. doi: 10.1182/blood.2021012852.
    PubMed     Abstract available


  72. JONAK C, Brunner PM
    Blood will tell: profiling Sezary syndrome.
    Blood. 2021;138:2450-2451.
    PubMed    


  73. SHOPSOWITZ KE, Slack GW
    B-lymphoblastic lymphoma presenting as a primary breast mass with periductal invasion.
    Blood. 2021;138:2593.
    PubMed    


  74. NAJIDH S, Tensen CP, van der Sluijs-Gelling AJ, Teodosio C, et al
    Improved Sezary cell detection and novel insights into immunophenotypic and molecular heterogeneity in Sezary syndrome.
    Blood. 2021;138:2539-2554.
    PubMed     Abstract available


  75. TONC E, Takeuchi Y, Chou C, Xia Y, et al
    Unexpected suppression of tumorigenesis by c-MYC via TFAP4-dependent restriction of stemness in B lymphocytes.
    Blood. 2021;138:2526-2538.
    PubMed     Abstract available


  76. GABALLA MR, Banerjee PP, Milton DR, Jiang X, et al
    Blinatumomab Maintenance After Allogeneic Hematopoietic Cell Transplantation for B-lineage Acute Lymphoblastic Leukemia.
    Blood. 2021 Dec 16. pii: 483090. doi: 10.1182/blood.2021013290.
    PubMed     Abstract available


  77. BUUS TB, Koralov SB
    Oncogenic fusions JAK up CD8+ cytotoxic CTCL.
    Blood. 2021;138:2311-2312.
    PubMed    


  78. LEE K, Evans MG, Yang L, Ng S, et al
    Primary cytotoxic T-cell lymphomas harbor recurrent targetable alterations in the JAK-STAT pathway.
    Blood. 2021;138:2435-2440.
    PubMed    


  79. ALCANTARA M, Houillier C, Blonski M, Rubio MT, et al
    CAR-T cell therapy in primary central nervous system lymphoma (PCNSL): the clinical experience of the French LOC network.
    Blood. 2021 Dec 6. pii: 482903. doi: 10.1182/blood.2021012932.
    PubMed    


  80. WILLIAMS AM, Mirzaei Salehabadi S, Xing M, Phillips NS, et al
    Modifiable Risk Factors for Neurocognitive and Psychosocial Problems After Hodgkin Lymphoma.
    Blood. 2021 Dec 3. pii: 482888. doi: 10.1182/blood.2021013167.
    PubMed     Abstract available


  81. WANG Z, Guo R, Trudeau SJ, Wolinsky E, et al
    CYB561A3 is the key lysosomal iron reductase required for Burkitt B-cell growth and survival.
    Blood. 2021;138:2216-2230.
    PubMed     Abstract available


    November 2021
  82. ISHIO T, Kumar S, Shimono J, Daenthanasanmak A, et al
    Genome-wide CRISPR screen identifies CDK6 as a therapeutic target in Adult T-cell leukemia/lymphoma.
    Blood. 2021 Nov 24. pii: 482776. doi: 10.1182/blood.2021012734.
    PubMed     Abstract available


  83. YANG G, Wang J, Tan L, Munshi M, et al
    The HCK/BTK inhibitor KIN-8194 is active in MYD88-driven lymphomas and overcomes mutated BTKCys481 ibrutinib resistance.
    Blood. 2021;138:1966-1979.
    PubMed     Abstract available


  84. WARD J, Berrien-Elliott MM, Gomez F, Luo J, et al
    Phase I/Dose Expansion Trial of Brentuximab vedotin/Lenalidomide in Relapsed or Refractory Diffuse Large B-cell Lymphoma.
    Blood. 2021 Nov 15. pii: 477971. doi: 10.1182/blood.2021011894.
    PubMed     Abstract available


  85. FANG H, Xu J
    Peripheral T-cell lymphoma with blastoid morphology and aberrant expression of multiple B-cell antigens.
    Blood. 2021;138:1906.
    PubMed    


  86. ZHANG J, Lucas D
    A young microenvironment promotes B-ALL in mice.
    Blood. 2021;138:1789-1790.
    PubMed    


  87. OLSEN EA, Whittaker S, Willemze R, Pinter-Brown L, et al
    Primary Cutaneous Lymphoma: Recommendations for Clinical Trial Design and Staging Update from the ISCL, USCLC, and EORTC.
    Blood. 2021 Nov 10. pii: 477944. doi: 10.1182/blood.2021012057.
    PubMed     Abstract available


    October 2021
  88. OKWAN-DUODU D, Huang Q
    Primary splenic Burkitt-like lymphoma with 11q aberration.
    Blood. 2021;138:1642.
    PubMed    


  89. KUPPERS R
    Sugar-modified B-cell receptors in DLBCL.
    Blood. 2021;138:1512-1514.
    PubMed    


  90. CHIODIN G, Allen JD, Bryant DJ, Rock P, et al
    Insertion of atypical glycans into the tumor antigen-binding site identifies DLBCLs with distinct origin and behavior.
    Blood. 2021;138:1570-1582.
    PubMed     Abstract available


  91. SCHAFF LR, Grommes C
    Primary Central Nervous System Lymphoma.
    Blood. 2021 Oct 26. pii: S0006-4971(21)01788-2. doi: 10.1182/blood.2020008377.
    PubMed     Abstract available


  92. KOGURE Y, Kameda T, Koya J, Yoshimitsu M, et al
    Whole-genome landscape of adult T-cell leukemia/lymphoma.
    Blood. 2021 Oct 25. pii: S0006-4971(21)01784-5. doi: 10.1182/blood.2021013568.
    PubMed     Abstract available


  93. EYRE TA, Cheah CY, Wang ML
    Therapeutic options for relapsed/refractory mantle cell lymphoma.
    Blood. 2021 Oct 22. pii: S0006-4971(21)01781-X. doi: 10.1182/blood.2021013326.
    PubMed     Abstract available


  94. WILSON MH, Gottschalk S
    Expect the unexpected: piggyBac and lymphoma.
    Blood. 2021;138:1379-1380.
    PubMed    


  95. GROS A, Merlio JP
    Single-cell trajectories in Sezary syndrome.
    Blood. 2021;138:1384-1386.
    PubMed    


  96. LIEBERS N, Speer C, Benning L, Bruch PM, et al
    Humoral and cellular responses after COVID-19 vaccination in anti-CD20 treated lymphoma patients.
    Blood. 2021 Oct 20. pii: 477393. doi: 10.1182/blood.2021013445.
    PubMed    


  97. JOHNSTON RL, Mottok A, Chan FC, Jiang A, et al
    Gene expression-based model predicts outcome in children with intermediate-risk classical Hodgkin lymphoma.
    Blood. 2021 Oct 18. pii: 477371. doi: 10.1182/blood.2021011941.
    PubMed     Abstract available


  98. KARACA ATABAY E, Mecca C, Wang Q, Ambrogio C, et al
    Tyrosine phosphatases regulate resistance to ALK inhibitors in ALK+ anaplastic large cell lymphoma.
    Blood. 2021 Oct 17. pii: 477348. doi: 10.1182/blood.2020008136.
    PubMed     Abstract available


  99. BONFIGLIO F, Bruscaggin A, Guidetti F, Terzi di Bergamo L, et al
    Genetic and Phenotypic Attributes of Splenic Marginal Zone Lymphoma.
    Blood. 2021 Oct 15. pii: 477330. doi: 10.1182/blood.2021012386.
    PubMed     Abstract available


  100. SANCHEZ-BEATO M
    PD-1 loss and T-cell exhaustion in CTCL tumoral T cells.
    Blood. 2021;138:1201-1203.
    PubMed    


  101. PARK J, Daniels J, Wartewig T, Ringbloom KG, et al
    Integrated genomic analyses of cutaneous T-cell lymphomas reveal the molecular bases for disease heterogeneity.
    Blood. 2021;138:1225-1236.
    PubMed     Abstract available


    September 2021
  102. XU D, Naresh KN
    Leukemic presentation of a highly aggressive ALK-negative anaplastic large cell lymphoma.
    Blood. 2021;138:1198.
    PubMed    


  103. STEPHENS DM, Byrd JC
    Resistance to Bruton tyrosine kinase inhibitors: the Achilles heel of their success story in lymphoid malignancies.
    Blood. 2021;138:1099-1109.
    PubMed     Abstract available


  104. MINDERMAN M, Amir A, Kraan W, Schilder-Tol EJM, et al
    Immune evasion in primary testicular and central nervous system lymphomas: HLA loss rather than 9p24.1/PD-L1/PD-L2 alterations.
    Blood. 2021;138:1194-1197.
    PubMed    


  105. LIU F, Gao Y, Xu B, Xiong S, et al
    PEG10 amplification at 7q21.3 potentiates large-cell transformation in cutaneous T-cell lymphoma.
    Blood. 2021 Sep 28. pii: 477066. doi: 10.1182/blood.2021012091.
    PubMed     Abstract available


  106. TENSEN CP, Quint KD, Vermeer MH
    Genetic and epigenetic insights into cutaneous T-cell lymphoma.
    Blood. 2021 Sep 27. pii: 477053. doi: 10.1182/blood.2019004256.
    PubMed     Abstract available


  107. PALLASCH CP
    Cell cycle control in Richter transformation.
    Blood. 2021;138:1005-1007.
    PubMed    


  108. GAO J, Sidiropoulou E, Walker I, Krupka JA, et al
    SGK1 mutations in DLBCL generate hyperstable protein neoisoforms that promote AKT independence.
    Blood. 2021;138:959-964.
    PubMed     Abstract available


  109. MAYERHOEFER M, Raderer M, Lamm W, Weber M, et al
    CXCR4 PET/MRI for follow-up of gastric mucosa-associated lymphoid tissue lymphoma after first-line H. pylori eradication.
    Blood. 2021 Sep 15. pii: 476918. doi: 10.1182/blood.2021013239.
    PubMed     Abstract available


  110. OLSZEWSKI A, Kurt H, Evens AM
    Defining and Treating High-grade B-cell lymphoma, NOS.
    Blood. 2021 Sep 15. pii: 476913. doi: 10.1182/blood.2020008374.
    PubMed     Abstract available


  111. DANIELS J, Choi J
    BACH2 is a putative T cell lymphoma tumor suppressor that may play a role in product-derived CAR-T cell lymphomas.
    Blood. 2021 Sep 9. pii: 476840. doi: 10.1182/blood.2021012641.
    PubMed    


  112. SAVAGE KJ
    Primary mediastinal Large B-cell Lymphoma.
    Blood. 2021 Sep 9. pii: 476814. doi: 10.1182/blood.2020008376.
    PubMed     Abstract available


  113. GERMANS SK, Chen M
    Myeloid/lymphoid neoplasm with FGFR1 rearrangement.
    Blood. 2021;138:912.
    PubMed    


  114. SCHMITT A, Xu W, Bucher P, Grimm M, et al
    Dimethyl fumarate induces ferroptosis and impairs NF-kappaB/STAT3 signaling in DLBCL.
    Blood. 2021;138:871-884.
    PubMed     Abstract available


  115. SCHMIDT RA, Lee AY
    How I treat and prevent venous thrombotic complications in patients with lymphoma.
    Blood. 2021 Sep 3. pii: 476786. doi: 10.1182/blood.2019003689.
    PubMed     Abstract available


  116. CARBONE A, Vaccher E, Gloghini A
    Hematological cancers in individuals infected by HIV.
    Blood. 2021 Sep 1. pii: 476746. doi: 10.1182/blood.2020005469.
    PubMed     Abstract available


    August 2021
  117. YAZDANBAKHSH K
    "Allo" from the (marginal) zone.
    Blood. 2021;138:595-596.
    PubMed    


  118. HERLING M, Wahnschaffe L
    Altered epigenetics at the center of NK-LGL leukemia.
    Blood. 2021;138:589-591.
    PubMed    


  119. CHOI Y, Diefenbach C
    Expanding landscape for relapsed Hodgkin lymphoma.
    Blood. 2021;138:421-422.
    PubMed    


  120. GALINDO-CAMPOS MA, Lutfi N, Bonnin S, Martinez C, et al
    Distinct roles for PARP-1 and PARP-2 in c-Myc-driven B-cell lymphoma in mice.
    Blood. 2021 Aug 6. pii: 476527. doi: 10.1182/blood.2021012805.
    PubMed     Abstract available


  121. ORICCHIO E
    Epigenetic balance in DLBCL.
    Blood. 2021;138:355-356.
    PubMed    


  122. HEWARD J, Konali L, D'Avola A, Close K, et al
    KDM5 inhibition offers a novel therapeutic strategy for the treatment of KMT2D mutant lymphomas.
    Blood. 2021;138:370-381.
    PubMed     Abstract available


    July 2021
  123. XU W, Berning P, Lenz G
    Targeting B-cell receptor and PI3K signaling in diffuse large B-cell lymphoma.
    Blood. 2021 Jul 28. pii: 476467. doi: 10.1182/blood.2020006784.
    PubMed     Abstract available


  124. ADVANI RH, Skrypets T, Civallero M, Spinner MA, et al
    Outcomes and prognostic factors in angioimmunoblastic T-cell lymphoma: final report from the international T-cell Project.
    Blood. 2021;138:213-220.
    PubMed     Abstract available


  125. DUNS G, Vigano E, Ennishi D, Sarkozy C, et al
    Characterization of DLBCL with a PMBL gene expression signature.
    Blood. 2021;138:136-148.
    PubMed     Abstract available


  126. TROTMAN J, Pettitt AR
    Is it time for PET-guided therapy in follicular lymphoma.
    Blood. 2021 Jul 14. pii: 476386. doi: 10.1182/blood.2020008243.
    PubMed     Abstract available


  127. HERRERA A, Cheng A, Mimitou EP, Seffens A, et al
    Multimodal single-cell analysis of cutaneous T cell lymphoma reveals distinct sub-clonal tissue-dependent signatures.
    Blood. 2021 Jul 7. pii: 476325. doi: 10.1182/blood.2020009346.
    PubMed     Abstract available


  128. ELUARD B, Nuan-Aliman S, Faumont N, Collares D, et al
    The alternative RelB NF-kappaB subunit is a novel critical player in diffuse large B-cell lymphoma.
    Blood. 2021 Jul 7. pii: 476326. doi: 10.1182/blood.2020010039.
    PubMed     Abstract available


  129. BURKE GAA
    Brentuximab vedotin: frontline help in ALCL.
    Blood. 2021;137:3581-3582.
    PubMed    


  130. LOWE EJ, Reilly AF, Lim MS, Gross TG, et al
    Brentuximab vedotin in combination with chemotherapy for pediatric patients with ALK+ ALCL: results of COG trial ANHL12P1.
    Blood. 2021;137:3595-3603.
    PubMed     Abstract available


    June 2021
  131. BALSAS P, Veloza L, Clot G, Sureda-Gomez M, et al
    SOX11, CD70 and Treg cells configure the tumor immune microenvironment of aggressive mantle cell lymphoma.
    Blood. 2021 Jun 29. pii: 476270. doi: 10.1182/blood.2020010527.
    PubMed     Abstract available


  132. GHIONE P, Gu JJ, Attwood K, Torka P, et al
    Impaired humoral responses to COVID-19 vaccination in patients with lymphoma receiving B-cell directed therapies.
    Blood. 2021 Jun 29. pii: 476275. doi: 10.1182/blood.2021012443.
    PubMed    


  133. REJESKI K, Perez Perez A, Sesques P, Hoster E, et al
    CAR-HEMATOTOX: A model for CAR T-cell related hematological toxicity in relapsed/refractory large B-cell lymphoma.
    Blood. 2021 Jun 24. pii: 476241. doi: 10.1182/blood.2020010543.
    PubMed     Abstract available


  134. MULLER MR
    A new option for Richter syndrome.
    Blood. 2021;137:3318-3319.
    PubMed    


  135. PEYRON JF
    Blocking RiBi to suppress MYC lymphomagenesis.
    Blood. 2021;137:3316-3318.
    PubMed    


  136. WILLIAMS ME
    Mantle cell lymphoma continues to surprise, and inform!
    Blood. 2021;137:3158-3160.
    PubMed    


  137. PASTORET C, Desmots F, Drillet G, Le Gallou S, et al
    Linking the KIR phenotype with STAT3 and TET2 mutations to identify chronic lymphoproliferative disorders of NK cells.
    Blood. 2021;137:3237-3250.
    PubMed     Abstract available


  138. KORONA B, Korona D, Zhao W, Wotherspoon A, et al
    GPR34 activation potentially bridges lymphoepithelial lesion to genesis of salivary gland MALT lymphoma.
    Blood. 2021 Jun 4. pii: 476070. doi: 10.1182/blood.2020010495.
    PubMed     Abstract available


  139. CAI J, Qing X
    Splenic marginal zone lymphoma with increased prolymphocytes.
    Blood. 2021;137:3150.
    PubMed    


    May 2021
  140. MASS J, Park DC
    Posttransplant T lymphoblastic lymphoma mimicking Burkitt lymphoma.
    Blood. 2021;137:3002.
    PubMed    


  141. PLAKS V, Rossi JM, Chou J, Wang L, et al
    CD19 target evasion as a mechanism of relapse in large B-cell lymphoma treated with axicabtagene ciloleucel.
    Blood. 2021 May 27. pii: 476038. doi: 10.1182/blood.2021010930.
    PubMed     Abstract available


  142. SONG S, Cao C, Choukrallah MA, Tang F, et al
    OBF1 and Oct factors control the germinal center transcriptional program.
    Blood. 2021;137:2920-2934.
    PubMed     Abstract available


  143. BOIKO S, Proia T, San Martin M, Gregory GP, et al
    Targeting Bfl-1 via acute CDK9 inhibition overcomes intrinsic BH3-mimetic resistance in lymphomas.
    Blood. 2021;137:2947-2957.
    PubMed     Abstract available


  144. SOUSSAIN C, Malaise D, Cassoux N
    Primary vitreoretinal lymphoma: A diagnostic and management challenge.
    Blood. 2021 May 25. pii: 476013. doi: 10.1182/blood.2020008235.
    PubMed     Abstract available


  145. MAAS-BAUER K, Lohmeyer JK, Hirai T, Lopes Ramos T, et al
    Invariant Natural Killer T Cell Subsets Have Diverse Graft-Versus-Host-Disease-Preventing and Anti-Tumor Effects.
    Blood. 2021 May 25. pii: 476015. doi: 10.1182/blood.2021010887.
    PubMed     Abstract available


  146. REIMANN M, Schrezenmeier J, Richter-Pechanska P, Dolnik A, et al
    Adaptive T-cell immunity controls senescence-prone MyD88- or CARD11-mutant B-cell lymphomas.
    Blood. 2021;137:2785-2799.
    PubMed     Abstract available


  147. BISHOP DC, Clancy LE, Simms R, Burgess J, et al
    Development of CAR T-cell lymphoma in two of ten patients effectively treated with piggyBac modified CD19 CAR T-cells.
    Blood. 2021 May 19. pii: 475980. doi: 10.1182/blood.2021010813.
    PubMed     Abstract available


  148. MCMILLAN A
    A new warhead in lymphoma therapy?
    Blood. 2021;137:2568-2570.
    PubMed    


  149. VOSE JM
    Outcomes for PTCL: which pathway to success?
    Blood. 2021;137:2570-2571.
    PubMed    


  150. SCHMITZ N, Truemper L, Bouabdallah K, Ziepert M, et al
    A randomized phase 3 trial of autologous vs allogeneic transplantation as part of first-line therapy in poor-risk peripheral T-NHL.
    Blood. 2021;137:2646-2656.
    PubMed     Abstract available


  151. MICKLETHWAITE KP, Gowrishankar K, Gloss BS, Li Z, et al
    Investigation of product derived lymphoma following infusion of piggyBac modified CD19 chimeric antigen receptor T-cells.
    Blood. 2021 May 11. pii: 475942. doi: 10.1182/blood.2021010858.
    PubMed     Abstract available


  152. SILVA AP, Almeida ARM, Cachucho A, Neto JL, et al
    Overexpression of wild type IL-7Ralpha promotes T-cell acute lymphoblastic leukemia/lymphoma.
    Blood. 2021 May 10. pii: 475938. doi: 10.1182/blood.2019000553.
    PubMed     Abstract available


  153. ZHAO Y, Wang E
    An effusion-based presentation of ALK- anaplastic large cell lymphoma.
    Blood. 2021;137:2563.
    PubMed    


  154. MAMLOUK O, Nair R, Iyer SP, Edwards A, et al
    Safety of CAR T-cell therapy in kidney transplant recipients.
    Blood. 2021;137:2558-2562.
    PubMed    


    April 2021
  155. DAVIES A
    DLBCL outcomes: much ventured, much GAINED.
    Blood. 2021;137:2277-2278.
    PubMed    


  156. LE GOUILL S, Ghesquieres H, Oberic L, Morschhauser F, et al
    Obinutuzumab vs rituximab for advanced DLBCL: a PET-guided and randomized phase 3 study by LYSA.
    Blood. 2021;137:2307-2320.
    PubMed     Abstract available


  157. EPPERLA N, Herrera AF
    How we incorporate novel agents into the treatment of classic Hodgkin lymphoma.
    Blood. 2021 Apr 22. pii: 475828. doi: 10.1182/blood.2020007900.
    PubMed     Abstract available


  158. BLOMBERY P, Lade S
    Defining double-hit lymphoma in the clinic.
    Blood. 2021;137:2132-2133.
    PubMed    


  159. CHATZIDIMITRIOU C, Vassilakopoulos TP
    Rapidly deteriorating B-CLL at presentation: clonally related Burkitt leukemia as an atypical Richter transformation?
    Blood. 2021;137:2272.
    PubMed    


  160. FALCHI L, Ma H, Klein S, Lue JK, et al
    Combined oral 5-azacytidine and romidepsin are highly effective in patients with PTCL: a multicenter phase 2 study.
    Blood. 2021;137:2161-2170.
    PubMed     Abstract available


  161. COLLINGE B, Ben-Neriah S, Chong L, Boyle M, et al
    The impact of MYC and BCL2 structural variants in tumors of DLBCL morphology and mechanisms of false-negative MYC IHC.
    Blood. 2021;137:2196-2208.
    PubMed     Abstract available


  162. BALA TANNAN N, Manzari MT, Herviou L, Da Silva Ferreira M, et al
    Tumor-targeted nanoparticles improve the therapeutic index of BCL2 and MCL1 dual inhibition.
    Blood. 2021;137:2057-2069.
    PubMed     Abstract available


  163. SEWASTIANIK T, Straubhaar JR, Zhao JJ, Samur MK, et al
    miR-15a/16-1 deletion in activated B cells promotes plasma cell and mature B-cell neoplasms.
    Blood. 2021;137:1905-1919.
    PubMed     Abstract available


  164. ADVANI R, Moskowitz AJ, Bartlett NL, Vose J, et al
    Brentuximab vedotin in combination with nivolumab in relapsed or refractory Hodgkin lymphoma: 3-year study results.
    Blood. 2021 Apr 7. pii: 475691. doi: 10.1182/blood.2020009178.
    PubMed     Abstract available



  165. Morschhauser F, Feugier P, Flinn IW, et al. A phase 2 study of venetoclax plus R-CHOP as first-line treatment of patients with diffuse large B-cell lymphoma. Blood. 2021;137(5):600-609.
    Blood. 2021;137:1844.
    PubMed    


  166. CHIHARA D, Dores G, Flowers C, Morton LM, et al
    The bidirectional increased risk of B-cell lymphoma and T-cell lymphoma.
    Blood. 2021 Apr 1. pii: 475679. doi: 10.1182/blood.2020010497.
    PubMed     Abstract available


  167. CAMPO E, Jaffe ES
    Taking gray zone lymphomas out of the shadows.
    Blood. 2021;137:1703-1704.
    PubMed    


    March 2021
  168. ADVANI R, Skrypets T, Civallero M, Spinner MA, et al
    Outcomes and Prognostic Factors in Angioimmunoblastic T cell Lymphoma: Final Report from the International TCell Project.
    Blood. 2021 Mar 30. pii: 475653. doi: 10.1182/blood.2020010387.
    PubMed     Abstract available


  169. YU X, Li W, Deng Q, Liu H, et al
    MYD88 L265P elicits mutation-specific ubiquitination to drive NF-kappaB activation and lymphomagenesis.
    Blood. 2021;137:1615-1627.
    PubMed     Abstract available


  170. HAN H, Fan G, Song S, Jiang Y, et al
    piRNA-30473 contributes to tumorigenesis and poor prognosis by regulating m6A RNA methylation in DLBCL.
    Blood. 2021;137:1603-1614.
    PubMed     Abstract available


  171. GUPTA M, Burns E, Georgantas NZ, Thierauf J, et al
    A Rapid Genotyping Panel for Detection of Primary Central Nervous System Lymphoma.
    Blood. 2021 Mar 18. pii: 475579. doi: 10.1182/blood.2020010137.
    PubMed     Abstract available



  172. Subsequent neoplasms in pediatric Hodgkin lymphoma.
    Blood. 2021;137:1562.
    PubMed    


  173. PATRIARCA A, Gaidano G
    Intravascular lymphoma: from vessels to genes.
    Blood. 2021;137:1438-1439.
    PubMed    


  174. BARTLETT NL
    Protect our children: Hodgkin lymphoma survivors.
    Blood. 2021;137:1433-1434.
    PubMed    


  175. ROSCHEWSKI M, Phelan JD
    Sorting biologic subtypes of primary CNS lymphoma.
    Blood. 2021;137:1436-1437.
    PubMed    


  176. HAEBE SE, Shree T, Sathe A, Day G, et al
    Single Cell Analysis Can Define Distinct Evolution of Tumor Sites in Follicular Lymphoma.
    Blood. 2021 Mar 16. pii: 475531. doi: 10.1182/blood.2020009855.
    PubMed     Abstract available


  177. TIAN XP, Ma SY, Young KH, Ong CK, et al
    A composite single-nucleotide polymorphism prediction signature for extranodal natural killer/T-cell lymphoma.
    Blood. 2021 Mar 16. pii: 475529. doi: 10.1182/blood.2020010637.
    PubMed     Abstract available


  178. MOSKOWITZ AJ
    PD-1 blockade for untreated Hodgkin lymphoma.
    Blood. 2021;137:1271-1272.
    PubMed    


  179. SHAH NN, Ahn KW, Litovich C, He Y, et al
    Is autologous transplant in relapsed DLBCL patients achieving only a PET+ PR appropriate in the CAR T-cell era?
    Blood. 2021;137:1416-1423.
    PubMed     Abstract available


  180. ELADL E, Chang H
    Bone marrow infiltration by plasmablastic neoplasm: plasmablastic myeloma or plasmablastic lymphoma?
    Blood. 2021;137:1268.
    PubMed    


  181. PIGNARRE A, Chatonnet F, Caron G, Haas M, et al
    Plasmablasts derive from CD23- activated B cells after the extinction of IL-4/STAT6 signaling and IRF4 induction.
    Blood. 2021;137:1166-1180.
    PubMed     Abstract available


    February 2021
  182. ILLERHAUS G
    CNS relapse in DLBCL: a calculable risk?
    Blood. 2021;137:1011-1012.
    PubMed    


  183. TRUJILLO JA, Godfrey J, Hu Y, Huang J, et al
    Primary resistance to CD19-directed chimeric antigen receptor T-cell therapy in T-cell/histiocyte-rich large B-cell lymphoma.
    Blood. 2021 Feb 24. pii: 475347. doi: 10.1182/blood.2020009148.
    PubMed    


  184. DUMONTET E, Pangault C, Roulois D, Desoteux M, et al
    Extracellular vesicles shed by follicular lymphoma B cells promote the polarization of bone marrow stromal cell niche.
    Blood. 2021 Feb 24. pii: 475345. doi: 10.1182/blood.2020008791.
    PubMed     Abstract available


  185. MADDOCKS K
    Building on BTK inhibition in MCL.
    Blood. 2021;137:861-862.
    PubMed    


  186. WIRTH A, Mikhaeel NG
    PET response-guided radiotherapy for advanced DLBCL?
    Blood. 2021;137:866-867.
    PubMed    


  187. RULAND J
    Synergy of MALT1 and mTOR inhibition in DLBCL.
    Blood. 2021;137:724-725.
    PubMed    


  188. MORSCHHAUSER F, Feugier P, Flinn IW, Gasiorowski R, et al
    A phase 2 study of venetoclax plus R-CHOP as first-line treatment for patients with diffuse large B-cell lymphoma.
    Blood. 2021;137:600-609.
    PubMed     Abstract available


  189. VITOLO U, Novo M
    Bcl-2 inhibition in DLBCL: "the times they are a-changing"?
    Blood. 2021;137:577-579.
    PubMed    


  190. CASULO C
    Checkpoint blockade in FL: eluding the king.
    Blood. 2021;137:581-582.
    PubMed    


  191. RAASTAD K, Huang Q
    Burkitt leukemia with immature B-cell phenotype mimicking acute lymphoblastic leukemia.
    Blood. 2021;137:718.
    PubMed    


  192. KOHLHAAS V, Blakemore SJ, Al-Maarri M, Nickel N, et al
    Active Akt signaling triggers CLL toward Richter transformation via overactivation of Notch1.
    Blood. 2021;137:646-660.
    PubMed     Abstract available


  193. DAHER M, Basar R, Gokdemir E, Baran N, et al
    Targeting a cytokine checkpoint enhances the fitness of armored cord blood CAR-NK cells.
    Blood. 2021;137:624-636.
    PubMed     Abstract available


  194. STRATI P, Ahmed S, Furqan F, Fayad LE, et al
    Prognostic Impact of Corticosteroids on Efficacy of Chimeric Antigen Receptor T-cell Therapy in Large B-cell Lymphoma.
    Blood. 2021 Feb 3. pii: 475147. doi: 10.1182/blood.2020008865.
    PubMed     Abstract available


    January 2021
  195. THURNER L, Fadle N, Bittenbring JT, Regitz E, et al
    LRPAP1-autoantibodies in mantle cell lymphoma are associated with superior outcome.
    Blood. 2021 Jan 29. pii: 475090. doi: 10.1182/blood.2020008835.
    PubMed     Abstract available


  196. ABEYKOON JP, Wu X, Nowakowski KE, Dasari S, et al
    Salicylates enhance CRM1 inhibitor antitumor activity by induction of S-phase arrest and impairment of DNA-damage repair.
    Blood. 2021;137:513-523.
    PubMed     Abstract available


  197. BOLEN CR, Mattiello F, Herold M, Hiddemann W, et al
    Treatment dependence of prognostic gene expression signatures in de novo follicular lymphoma.
    Blood. 2021 Jan 25. pii: 475041. doi: 10.1182/blood.2020008119.
    PubMed    


  198. ROSCHEWSKI M
    The balancing act in Burkitt lymphoma.
    Blood. 2021;137:289-291.
    PubMed    


  199. GAUTHIER J, Bezerra ED, Hirayama AV, Fiorenza S, et al
    Factors associated with outcomes after a second CD19-targeted CAR T-cell infusion for refractory B-cell malignancies.
    Blood. 2021;137:323-335.
    PubMed     Abstract available


  200. JAIN MD, Zhao H, Wang X, Atkins R, et al
    Tumor interferon signaling and suppressive myeloid cells associate with CAR T cell failure in large B cell lymphoma.
    Blood. 2021 Jan 15. pii: 474963. doi: 10.1182/blood.2020007445.
    PubMed     Abstract available


  201. MASS J, Alobeid B
    Composite mantle cell lymphoma and small lymphocytic lymphoma in a lymph node.
    Blood. 2021;137:282.
    PubMed    


  202. ISSA D, Seefat RL, Visser O, Zweegman S, et al
    Primary therapy and survival in patients with Burkitt lymphoma in the Netherlands: a population-based study, 1989-2018.
    Blood. 2021 Jan 14. pii: 474957. doi: 10.1182/blood.2020009552.
    PubMed    


  203. DOMOSTEGUI A, Peddigari S, Mercer CA, Iannizzotto F, et al
    Impaired ribosome biogenesis checkpoint activation induces p53-dependent MCL-1 degradation and MYC-driven lymphoma death.
    Blood. 2021 Jan 14. pii: 474958. doi: 10.1182/blood.2020007452.
    PubMed     Abstract available


  204. LOSSOS IS
    Stage I DLBCL: extranodal may mean extra radiation.
    Blood. 2021;137:3-5.
    PubMed    


    December 2020
  205. KHANLARI M, Medeiros LJ
    ALK+ large B-cell lymphoma with aberrant expression of CD3.
    Blood. 2020;136:3086.
    PubMed    


  206. SHIMADA K, Yoshida K, Suzuki Y, Iriyama C, et al
    Frequent Genetic Alterations in Immune Checkpoint-Related Genes in Intravascular Large B-Cell Lymphoma.
    Blood. 2020 Dec 24. pii: 474768. doi: 10.1182/blood.2020007245.
    PubMed     Abstract available


  207. FORBES LR
    Distract NK cell killing: give them a fatty meal.
    Blood. 2020;136:2969-2970.
    PubMed    


  208. FUKUMOTO K, Sakata-Yanagimoto M, Fujisawa M, Sakamoto T, et al
    VAV1 mutations contribute to development of T-cell neoplasms in mice.
    Blood. 2020;136:3018-3032.
    PubMed     Abstract available


  209. BAIRD JH, Frank MJ, Craig J, Patel S, et al
    CD22-Directed CAR T-Cell Therapy Induces Complete Remissions in CD19-Directed CAR-Refractory Large B-Cell Lymphoma.
    Blood. 2020 Dec 18. pii: 474751. doi: 10.1182/blood.2020009432.
    PubMed     Abstract available


  210. DE LEVAL L
    Chromosomes in breast lymphoma.
    Blood. 2020;136:2848-2849.
    PubMed    


  211. LOS-DE VRIES GT, de Boer M, van Dijk E, Stathi P, et al
    Chromosome 20 loss is characteristic of breast implant-associated anaplastic large cell lymphoma.
    Blood. 2020;136:2927-2932.
    PubMed     Abstract available


  212. YOUNES S, Natkunam Y
    Elusive sentinels at the Hodgkin checkpoint.
    Blood. 2020;136:2841-2842.
    PubMed    


  213. GIULINO-ROTH L, Pei Q, Buxton A, Bush R, et al
    Subsequent malignant neoplasms among children with Hodgkin lymphoma: A report from the Children's Oncology Group.
    Blood. 2020 Dec 11. pii: 474601. doi: 10.1182/blood.2020007225.
    PubMed     Abstract available


  214. ELNAIR R, Lunning MA
    Checkpoint inhibition in ENKTL: Kno_le_ge G_ps.
    Blood. 2020;136:2721-2722.
    PubMed    


  215. HAWKES EA
    Can PET eradicate irradiation in PMBCL?
    Blood. 2020;136:2725-2726.
    PubMed    


  216. FOWLER N
    BCL-2 inhibition in follicular lymphoma: can we tip the scales?
    Blood. 2020;136:2598-2600.
    PubMed    


    November 2020
  217. LIU H, Audino AN
    Metastatic nasopharyngeal carcinoma mimicking nodular sclerosis Hodgkin lymphoma.
    Blood. 2020;136:2596.
    PubMed    


  218. ELLIN F, Savage KJ
    Is the CNS-PINK the new CNS risk model in ENKTL?
    Blood. 2020;136:2486-2487.
    PubMed    


  219. HAMADANI M, Radford J, Carlo-Stella C, Caimi PF, et al
    Final Results of a Phase 1 Study of Loncastuximab Tesirine in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma.
    Blood. 2020 Nov 19. pii: 474210. doi: 10.1182/blood.2020007512.
    PubMed     Abstract available


  220. CONNORS JM
    Hodgkin lymphoma: outsmarting HRS cells.
    Blood. 2020;136:2362-2364.
    PubMed    


  221. STEIDL C
    Architecture and interior design of Hodgkin lymphoma.
    Blood. 2020;136:2367-2369.
    PubMed    


  222. YANG H, Green MR
    Harnessing lymphoma epigenetics to improve therapies.
    Blood. 2020 Nov 18. pii: 474151. doi: 10.1182/blood.2020006908.
    PubMed     Abstract available


  223. KLINTMAN J, Appleby N, Stamatopoulos B, Ridout K, et al
    Genomic and transcriptomic correlates of Richter's transformation in Chronic Lymphocytic Leukemia.
    Blood. 2020 Nov 18. pii: 474199. doi: 10.1182/blood.2020005650.
    PubMed     Abstract available


  224. GANDHI MK, Hoang T, Law SC, Brosda S, et al
    EBV-tissue positive primary CNS lymphoma occurring after immunosuppression is a distinct immunobiological entity.
    Blood. 2020 Nov 17. pii: 474186. doi: 10.1182/blood.2020008520.
    PubMed     Abstract available


  225. LE GOUILL S, Morschhauser F, Chiron D, Bouabdallah K, et al
    Ibrutinib, Obinutuzumab And Venetoclax In Relapsed and Untreated Patients with Mantle-Cell Lymphoma, a phase I/II trial.
    Blood. 2020 Nov 12. pii: 474141. doi: 10.1182/blood.2020008727.
    PubMed     Abstract available


  226. VENTURUTTI L, Melnick AM
    The dangers of deja vu: memory B cells as the cells of origin of ABC-DLBCLs.
    Blood. 2020;136:2263-2274.
    PubMed     Abstract available


  227. GANG M, Marin ND, Wong P, Neal CC, et al
    CAR-modified memory-like NK cells exhibit potent responses to NK-resistant lymphomas.
    Blood. 2020;136:2308-2318.
    PubMed     Abstract available


  228. CROMBIE JL, LaCasce AS
    The treatment of Burkitt lymphoma in adults.
    Blood. 2020 Nov 10. pii: 474125. doi: 10.1182/blood.2019004099.
    PubMed     Abstract available


  229. SPIEGEL JY, Dahiya S, Jain MD, Tamaresis JS, et al
    Outcomes of Patients with Large B-cell Lymphoma Progressing after Axicabtagene Ciloleucel.
    Blood. 2020 Nov 6. pii: 474111. doi: 10.1182/blood.2020006245.
    PubMed    


  230. KHANAM T, Sandmann S, Seggewiss J, Ruether CM, et al
    Integrative genomic analysis of pediatric T- cell lymphoblastic lymphoma reveals candidates of clinical significance.
    Blood. 2020 Nov 5. pii: 474099. doi: 10.1182/blood.2020005381.
    PubMed     Abstract available


  231. VERGE V, Soufan R
    COVID-19-induced atypical pulmonary lymphocytes.
    Blood. 2020;136:2241.
    PubMed    


    October 2020
  232. REINKE S, Brockelmann PJ, Iaccarino I, Garcia-Marquez MA, et al
    Tumor and microenvironment response but no cytotoxic T-cell activation in classic Hodgkin lymphoma treated with anti-PD1.
    Blood. 2020 Oct 28. pii: 469788. doi: 10.1182/blood.2020008553.
    PubMed     Abstract available


  233. COOK LB, Phillips AA
    How I treat Adult T-cell leukemia/lymphoma.
    Blood. 2020 Oct 19. pii: 469694. doi: 10.1182/blood.2019004045.
    PubMed     Abstract available


  234. FARHAT H, Ghanem H
    Primary cutaneous gammadelta T-cell lymphoma with secondary lung involvement.
    Blood. 2020;136:1892.
    PubMed    


  235. HU G, Feldman AL
    Drivers of crizotinib resistance in ALK+ ALCL.
    Blood. 2020;136:1573-1575.
    PubMed    


  236. SCHUSTER SJ
    NextGen CARs: the race is on.
    Blood. 2020;136:1570-1571.
    PubMed    


    September 2020
  237. ALLEN PB, Savas H, Evens AM, Advani R, et al
    Pembrolizumab followed by AVD in untreated early unfavorable and advanced stage classical Hodgkin lymphoma.
    Blood. 2020 Sep 29. pii: 463993. doi: 10.1182/blood.2020007400.
    PubMed     Abstract available


  238. TWA DDW, Lee DG, Tan KL, Slack GW, et al
    Genomic predictors of central nervous system relapse in primary testicular diffuse large B-cell lymphoma (DLBCL).
    Blood. 2020 Sep 23. pii: 463849. doi: 10.1182/blood.2020006338.
    PubMed    


  239. SARKOZY C, Hung SS, Chavez EA, Duns G, et al
    Mutational Landscape of Grey Zone Lymphoma.
    Blood. 2020 Sep 22. pii: 463845. doi: 10.1182/blood.2020007507.
    PubMed     Abstract available


  240. MORSCHHAUSER F, Feugier P, Flinn IW, Gasiorowski R, et al
    A phase II study of venetoclax plus R-CHOP as first-line treatment for patients with diffuse large B-cell lymphoma.
    Blood. 2020 Sep 21. pii: 463804. doi: 10.1182/blood.2020006578.
    PubMed     Abstract available


  241. SANDER B
    Under the cover of mantle cell lymphoma.
    Blood. 2020;136:1378-1379.
    PubMed    


  242. STRATI P, Jain P, Johnson RJ, Forbes SG, et al
    Long Term Follow-Up of Lenalidomide and Rituximab as Initial Treatment of Follicular Lymphoma.
    Blood. 2020 Sep 15. pii: 463764. doi: 10.1182/blood.2020007994.
    PubMed    


  243. ESTEVE-PUIG R, Climent F, Pineyro D, Domingo-Domenech E, et al
    Epigenetic Loss of m1A RNA Demethylase ALKBH3 in Hodgkin Lymphoma Targets Collagen Conferring Poor Clinical Outcome.
    Blood. 2020 Sep 11. pii: 463753. doi: 10.1182/blood.2020005823.
    PubMed    


  244. WITZIG TE
    Myc matters in HIV-associated lymphoma.
    Blood. 2020;136:1217-1218.
    PubMed    


  245. LOS-DE VRIES GT, De Boer M, van Dijk E, Stathi P, et al
    Chromosome 20 loss is characteristic for Breast implant-Associated Anaplastic Large Cell Lymphoma.
    Blood. 2020 Sep 8. pii: 463711. doi: 10.1182/blood.2020005372.
    PubMed     Abstract available


  246. RABOSO-GALLEGO J, Casado-Garcia A, Jiang X, Isidro-Hernandez M, et al
    Conditional expression of HGAL leads to the development of diffuse large B-cell lymphoma in mice.
    Blood. 2020 Sep 6. pii: 464123. doi: 10.1182/blood.2020004996.
    PubMed     Abstract available


  247. ORTUNO FJ, Amigo ML
    Triple-hit lymphoma with hyperbasophilic Burkitt-like morphology and solely bone marrow/leukemic phase presentation.
    Blood. 2020;136:1212.
    PubMed    


  248. EICHENAUER DA, Engert A
    How I treat nodular lymphocyte-predominant Hodgkin Lymphoma.
    Blood. 2020 Sep 2. pii: 463607. doi: 10.1182/blood.2019004044.
    PubMed     Abstract available


  249. OLLILA TA, Kurt H, Waroich J, Vatkevich J, et al
    Genomic subtypes may predict the risk of central nervous system recurrence in diffuse large B-cell lymphoma.
    Blood. 2020 Sep 2. pii: 463609. doi: 10.1182/blood.2020007236.
    PubMed    


  250. FREEMAN CL, Savage KJ, Villa D, Scott DW, et al
    Long-Term Results of PET-Guided Radiation in Advanced-Stage Diffuse Large B-Cell Lymphoma Patients Treated with R-CHOP.
    Blood. 2020 Sep 1. pii: 463600. doi: 10.1182/blood.2020005846.
    PubMed     Abstract available


  251. GRIFFIN GK, Weirather JL, Roemer M, Lipschitz M, et al
    Spatial Signatures Identify Immune Escape via PD-1 as a Defining Feature of T-cell/Histiocyte-rich Large B-cell Lymphoma.
    Blood. 2020 Sep 1. pii: 463601. doi: 10.1182/blood.2020006464.
    PubMed     Abstract available


    August 2020
  252. ARMAND P, Janssens AM, Gritti G, Radford J, et al
    Efficacy and safety results from CheckMate 140, a phase 2 study of nivolumab for relapsed/refractory follicular lymphoma.
    Blood. 2020 Aug 31. pii: 463592. doi: 10.1182/blood.2019004753.
    PubMed     Abstract available


  253. WANG HY, Tzachanis D
    Extramedullary early T-cell precursor acute lymphoblastic lymphoma presenting as blast crisis of CML.
    Blood. 2020;136:1112.
    PubMed    


  254. ZHANG Q, Casanova JL
    Human TET2 bridges cancer and immunity.
    Blood. 2020;136:1018-1019.
    PubMed    



  255. Long-term limited-stage follicular lymphoma study.
    Blood. 2020;136:1013.
    PubMed    


  256. KOBAYASHI T, Lam PY, Jiang H, Bednarska K, et al
    Increased lipid metabolism impairs NK cell function and mediates adaptation to the lymphoma environment.
    Blood. 2020 Aug 20. pii: 463339. doi: 10.1182/blood.2020005602.
    PubMed     Abstract available


  257. DUNLEAVY K, McLintock C
    How I Treat Lymphoma in Pregnancy.
    Blood. 2020 Aug 13. pii: 463256. doi: 10.1182/blood.2019000961.
    PubMed     Abstract available


  258. ZINZANI PL, Flinn IW, Yuen SLS, Topp MS, et al
    Venetoclax-rituximab +/- bendamustine vs bendamustine-rituximab in relapsed/refractory follicular lymphoma: CONTRALTO.
    Blood. 2020 Aug 12. pii: 461787. doi: 10.1182/blood.2020005588.
    PubMed     Abstract available


  259. FONTAN GABAS L, Goldstein RL, Casalena G, Durant M, et al
    Identification of MALT1 Feedback Mechanisms Enables Rational Design of Potent Anti-Lymphoma Regimens for ABC-DLBCL.
    Blood. 2020 Aug 12. pii: 461786. doi: 10.1182/blood.2019004713.
    PubMed     Abstract available


  260. KIM SJ, Lim JQ, Laurensia Y, Cho J, et al
    Avelumab for the treatment of relapsed or refractory extranodal NK/T-cell lymphoma: an open-label phase 2 study.
    Blood. 2020 Aug 7. pii: 461762. doi: 10.1182/blood.2020007247.
    PubMed     Abstract available


  261. GRANAI M, Lazzi S
    Early pattern of large B-cell lymphoma with IRF4 rearrangement.
    Blood. 2020;136:769.
    PubMed    


  262. POMERANTZ JL
    HOIP for targeting diffuse large B-cell lymphoma.
    Blood. 2020;136:646-647.
    PubMed    


  263. JO T, Nishikori M, Kogure Y, Arima H, et al
    LUBAC accelerates B-cell lymphomagenesis by conferring resistance to genotoxic stress on B cells.
    Blood. 2020;136:684-697.
    PubMed     Abstract available


  264. PRO B, Allen PB, Behdad A
    Hepatosplenic T-cell lymphoma: A rare but challenging entity.
    Blood. 2020 Aug 5. pii: 461707. doi: 10.1182/blood.2019004118.
    PubMed     Abstract available


    July 2020
  265. BARTLETT NL, Herrera AF, Domingo-Domenech E, Mehta A, et al
    A phase 1b study of AFM13 in combination with pembrolizumab in patients with relapsed or refractory Hodgkin lymphoma.
    Blood. 2020 Jul 30. pii: 461621. doi: 10.1182/blood.2019004701.
    PubMed     Abstract available


  266. BOBILLO S, Joffe E, Lavery JA, Sermer D, et al
    Clinical Characteristics and Outcomes of Extranodal Stage I Diffuse Large B Cell Lymphoma in The Rituximab-Era.
    Blood. 2020 Jul 30. pii: 461623. doi: 10.1182/blood.2020005112.
    PubMed     Abstract available


  267. ALBERT MH, Hauck F
    EBV-triggered hemophagocytic lymphohistiocytosis in a boy with a history of non-Hodgkin lymphoma.
    Blood. 2020;136:644.
    PubMed    


  268. WEIGERT O
    The different flavors and splices of MCL.
    Blood. 2020;136:526-527.
    PubMed    


  269. EVENS AM, Danilov AV, Jagadeesh D, Sperling AL, et al
    Burkitt Lymphoma in the Modern Era: Real World Outcomes and Prognostication Across 30 US Cancer Centers.
    Blood. 2020 Jul 14. pii: 461327. doi: 10.1182/blood.2020006926.
    PubMed     Abstract available



  270. Kuruvilla J, Savona M, Baz R, et al. Selective inhibition of nuclear export with selinexor in patients with non-Hodgkin lymphoma. Blood. 2017;129(24):3175-3183.
    Blood. 2020;136:259.
    PubMed    


  271. FRIEDRICH C, Barreau S
    A splenic lymphoma/leukemia with a spontaneous blast decrease without treatment.
    Blood. 2020;136:148.
    PubMed    


  272. LURAIN K, Uldrick TS, Ramaswami R, Polizzotto M, et al
    Treatment of HIV-associated Primary CNS Lymphoma with Antiretroviral Therapy, Rituximab, and High-Dose Methotrexate.
    Blood. 2020 Jul 1. pii: 461242. doi: 10.1182/blood.2020006048.
    PubMed    


    June 2020
  273. HAYDEN A, Tonseth P, Lee DG, Villa D, et al
    Outcome of Primary Mediastinal Large B-cell Lymphoma Using R-CHOP: Impact of a PET Adapted Approach.
    Blood. 2020 Jun 30. pii: 461229. doi: 10.1182/blood.2019004296.
    PubMed     Abstract available


  274. VELDMAN J, Visser L, Huberts-Kregel M, Muller N, et al
    Rosetting T cells in Hodgkin lymphoma are activated by immunological synapse components HLA class II and CD58.
    Blood. 2020 Jun 26. pii: 461197. doi: 10.1182/blood.2020005546.
    PubMed     Abstract available


  275. LINDHOLM KE, Ewalt MD
    Hemophagocytic syndrome-associated intravascular large B-cell lymphoma.
    Blood. 2020;135:2432.
    PubMed    


  276. MOSKOWITZ AJ
    NLP Hodgkin lymphoma: can we get away with less?
    Blood. 2020;135:2329-2330.
    PubMed    


  277. NADEU F, Martin-Garcia D, Clot G, Diaz-Navarro A, et al
    Genomic and epigenomic insights into the origin, pathogenesis and clinical behavior of mantle cell lymphoma subtypes.
    Blood. 2020 Jun 25. pii: 461130. doi: 10.1182/blood.2020005289.
    PubMed     Abstract available


  278. KIM H, Jeong H, Yamaguchi M, Sohn I, et al
    Prediction and prevention of central nervous system relapse in patients with extranodal natural killer/T-cell lymphoma.
    Blood. 2020 Jun 25. pii: 461129. doi: 10.1182/blood.2020005026.
    PubMed     Abstract available


  279. PROKOPH N, Probst NA, Lee LC, Monahan JM, et al
    IL10RA Modulates Crizotinib Sensitivity in NPM1-ALK-positive Anaplastic Large Cell Lymphoma.
    Blood. 2020 Jun 23. pii: 461097. doi: 10.1182/blood.2019003793.
    PubMed     Abstract available


  280. TONG C, Zhang Y, Liu Y, Ji X, et al
    Optimized tandem CD19/CD20 CAR-engineered T cells in refractory/relapsed B cell lymphoma.
    Blood. 2020 Jun 18. pii: 461029. doi: 10.1182/blood.2020005278.
    PubMed     Abstract available


  281. MEIGNAN M, Gallamini A
    DeltaSUVmax for interim PET in DLBCL: old is new.
    Blood. 2020;135:2202-2203.
    PubMed    


  282. ZHANG Q, Orlando E, Wang H, Bogusz AM, et al
    Transdifferentiation of lymphoma into sarcoma associated with profound reprogramming of epigenome.
    Blood. 2020 Jun 9. pii: 460737. doi: 10.1182/blood.2020005123.
    PubMed    


  283. CHEN J, Goyal N, Dai L, Lin Z, et al
    Developing new ceramide analogs and identifying novel sphingolipid controlled genes against a virus-associated lymphoma.
    Blood. 2020 Jun 9. pii: 460736. doi: 10.1182/blood.2020005569.
    PubMed     Abstract available


  284. STREMENOVA SPEGAROVA J, Lawless D, Mohamad SMB, Engelhardt KR, et al
    Germline TET2 Loss-Of-Function Causes Childhood Immunodeficiency And Lymphoma.
    Blood. 2020 Jun 9. pii: 460739. doi: 10.1182/blood.2020005844.
    PubMed     Abstract available


  285. LINK BK
    Foreseeing what is to happen in DLBCL.
    Blood. 2020;135:2014-2015.
    PubMed    


  286. BISHOP MR
    The benefit of CAR T cells in older patients.
    Blood. 2020;135:2020-2021.
    PubMed    


  287. RATNER L
    Predicting the future: adult T-cell leukemia.
    Blood. 2020;135:2013-2014.
    PubMed    


    May 2020
  288. ESKELUND CW, Husby S, Favero F, Klausen TW, et al
    Clonal hematopoiesis evolves from pretreatment clones and stabilizes after end of chemotherapy in patients with MCL.
    Blood. 2020;135:2000-2004.
    PubMed    


  289. DE BOER M, Hauptmann M, Hijmering NJ, van Noesel CJM, et al
    Increased prevalence of BRCA1/2 mutations in women with macro-textured breast implants and anaplastic large cell lymphoma of the breast.
    Blood. 2020 May 26. pii: 457298. doi: 10.1182/blood.2019004498.
    PubMed    


  290. GAYDOSIK AM, Queen DS, Trager MH, Akilov OE, et al
    Genome-wide transcriptome analysis of the STAT6-regulated genes in advanced-stage cutaneous T-cell lymphoma.
    Blood. 2020 May 21. pii: 456039. doi: 10.1182/blood.2019004725.
    PubMed     Abstract available


  291. MCGINNIS E, Farinha P
    Intravascular large B-cell lymphoma presenting with acute encephalopathy.
    Blood. 2020;135:1916.
    PubMed    


  292. HESLOP HE
    Sensitizing Burkitt lymphoma to EBV-CTLs.
    Blood. 2020;135:1822-1823.
    PubMed    


  293. YAHALOM J, Dabaja BS, Ricardi U, Ng A, et al
    ILROG emergency guidelines for radiation therapy of hematological malignancies during the COVID-19 pandemic.
    Blood. 2020;135:1829-1832.
    PubMed     Abstract available


  294. DALTON T, Doubrovina E, Pankov D, Reynolds R, et al
    Epigenetic reprogramming sensitizes immunologically silent EBV+ lymphomas to virus-directed immunotherapy.
    Blood. 2020;135:1870-1881.
    PubMed     Abstract available


  295. RAMOS JC, Sparano JA, Chadburn A, Reid EG, et al
    Impact of Myc in HIV-associated Non-Hodgkin Lymphomas Treated with EPOCH, and Outcomes with Vorinostat (AMC075 Trial).
    Blood. 2020 May 19. pii: 456029. doi: 10.1182/blood.2019003959.
    PubMed     Abstract available


  296. JELINEK T, Zuchnicka J
    Peripheral T-cell lymphoma, NOS, with rapidly progressing leukocytosis mimicking acute lymphoblastic leukemia.
    Blood. 2020;135:1816.
    PubMed    


  297. MORIN RD, Scott DW
    DLBCL subclassification: divide and conquer?
    Blood. 2020;135:1722-1724.
    PubMed    


  298. LACY SE, Barrans SL, Beer PA, Painter D, et al
    Targeted sequencing in DLBCL, molecular subtypes, and outcomes: a Haematological Malignancy Research Network report.
    Blood. 2020;135:1759-1771.
    PubMed     Abstract available


  299. GERBY B, Hoang T
    A targetable cue in T-cell malignancy.
    Blood. 2020;135:1616-1617.
    PubMed    


    April 2020
  300. LIAPIS K, Paterakis G
    Circulating angioimmunoblastic T-cell lymphoma cells.
    Blood. 2020;135:1607.
    PubMed    


  301. SWENSON S, Gilbreath T, Vahle HE, Hynes-Smith RW, et al
    E3 Ligase, UBR5, HECT domain mutations in lymphoma control maturation of B cells.
    Blood. 2020 Apr 23. pii: 454471. doi: 10.1182/blood.2019002102.
    PubMed     Abstract available



  302. Hilton LK, Tang J, Ben-Neriah S, et al. The double-hit signature identifies double-hit diffuse large B-cell lymphoma with genetic events cryptic to FISH. Blood. 2019;134(18):1528-1532.
    Blood. 2020;135:1507.
    PubMed    


  303. WHITLOCK JA
    Go with the flow: simplified MRD in LMIC ALL.
    Blood. 2020;135:1414-1415.
    PubMed    


  304. ZHANG W, Yang J, Zhou C, Hu B, et al
    Early response observed in pediatric patients with relapsed/refractory Burkitt lymphoma treated with chimeric antigen receptor T cells.
    Blood. 2020 Apr 22. pii: 454449. doi: 10.1182/blood.2019002008.
    PubMed    


  305. LO A, Campbell BA, Pickles T, Aquino-Parsons C, et al
    Long-Term Outcomes for Patients With Limited-Stage Follicular Lymphoma: Update of a Population-based Study.
    Blood. 2020 Apr 22. pii: 454451. doi: 10.1182/blood.2019004588.
    PubMed    


  306. CHESON BD
    Predicting the future for DLBCL.
    Blood. 2020;135:1308-1309.
    PubMed    


  307. MELANI C, Jaffe ES, Wilson WH
    Pathobiology and treatment of lymphomatoid granulomatosis, a rare EBV-driven disorder.
    Blood. 2020;135:1344-1352.
    PubMed     Abstract available


  308. VERCELLINO L, Cottereau AS, Casasnovas O, Tilly H, et al
    High total metabolic tumor volume at baseline predicts survival independent of response to therapy.
    Blood. 2020;135:1396-1405.
    PubMed     Abstract available


  309. MIKHAEEL NG
    Hotter is not more aggressive: baseline SUVmax in FL.
    Blood. 2020;135:1191-1192.
    PubMed    


  310. ALDERUCCIO JP, Isrow D, Reis IM, Iyer SG, et al
    Diagnostic bone marrow biopsy in patients with stage I EMZL treated with radiation therapy: needed or not?
    Blood. 2020;135:1299-1302.
    PubMed    


  311. KRISHNAMURTHY K, Sriganeshan V
    Extracavitary primary effusion lymphoma presenting as a thalamic mass in a patient with multicentric Castleman disease.
    Blood. 2020;135:1190.
    PubMed    


  312. SIMKINS A, Dunleavy K
    Tackling Burkitt when it's back.
    Blood. 2020;135:1078-1080.
    PubMed    


  313. FLOWERS C, Leonard JP, Fowler N
    Lenalidomide in follicular lymphoma.
    Blood. 2020 Apr 1. pii: 454206. doi: 10.1182/blood.2019001751.
    PubMed     Abstract available


    March 2020
  314. JANZ S
    MYC needs MNT to drive B cells over the edge.
    Blood. 2020;135:977-978.
    PubMed    


  315. NGUYEN HV, Vandenberg CJ, Ng AP, Robati MR, et al
    Development and survival of MYC-driven lymphomas require the MYC antagonist MNT to curb MYC-induced apoptosis.
    Blood. 2020;135:1019-1031.
    PubMed     Abstract available


  316. RISUENO A, Hagner PR, Towfic F, Fontanillo C, et al
    Leveraging gene expression subgroups to classify DLBCL patients and select for clinical benefit from a novel agent.
    Blood. 2020;135:1008-1018.
    PubMed     Abstract available


  317. CARPIO C, Bouabdallah R, Ysebaert L, Sancho JM, et al
    Avadomide monotherapy in relapsed/refractory DLBCL: safety, efficacy, and a predictive gene classifier.
    Blood. 2020;135:996-1007.
    PubMed     Abstract available


  318. CHIANG MY
    Tearing ATL apart to find HTLV's sinister plans.
    Blood. 2020;135:887-889.
    PubMed    


  319. RUPPERT AS, Dixon JG, Salles GA, Wall A, et al
    International prognostic indices in diffuse large B-cell lymphoma (DLBCL): a comparison of IPI, R-IPI and NCCN-IPI.
    Blood. 2020 Mar 13. pii: 452696. doi: 10.1182/blood.2019002729.
    PubMed     Abstract available


  320. SCHODER H, Polley MY, Knopp MV, Hall NC, et al
    Prognostic Value of Interim FDG-PET in Diffuse Large Cell Lymphoma: Results from the CALGB 50303 Clinical Trial.
    Blood. 2020 Mar 13. pii: 452697. doi: 10.1182/blood.2019003277.
    PubMed     Abstract available


  321. ROULLAND S
    Sugar-coated BCR kept during FL clonal evolution.
    Blood. 2020;135:784-785.
    PubMed    


  322. SROUR SA, Singh H, McCarty J, de Groot E, et al
    Long-term outcomes of Sleeping Beauty-generated CD19-specific CAR T-cell therapy for relapsed-refractory B-cell lymphomas.
    Blood. 2020;135:862-865.
    PubMed    


  323. DIEHL LF
    The efficacy-toxicity conundrum: breaking the mold.
    Blood. 2020;135:704-706.
    PubMed    


    February 2020
  324. DUFVA O, Koski J, Maliniemi P, Ianevski A, et al
    Integrated drug profiling and CRISPR screening identify essential pathways for CAR T-cell cytotoxicity.
    Blood. 2020;135:597-609.
    PubMed     Abstract available


  325. DE SMEDT R, Morscio J, Reunes L, Roels J, et al
    Targeting cytokine and therapy induced PIM1 activation in T-cell acute lymphoblastic leukemia and lymphoma.
    Blood. 2020 Feb 13. pii: 452489. doi: 10.1182/blood.2019003880.
    PubMed     Abstract available


    January 2020
  326. LAURENT C, Nicolae A, Laurent C, Le Bras F, et al
    Gene alterations in epigenetic modifiers and JAK-STAT signaling are frequent in breast implant-associated ALCL.
    Blood. 2020;135:360-370.
    PubMed     Abstract available


  327. BASSET M, Defrancesco I, Milani P, Nuvolone M, et al
    Nonlymphoplasmacytic lymphomas associated with light-chain amyloidosis.
    Blood. 2020;135:293-296.
    PubMed    


  328. STAIGER AM, Hoster E, Jurinovic V, Winter S, et al
    Localized- and advanced-stage follicular lymphomas differ in their gene expression profiles.
    Blood. 2020;135:181-190.
    PubMed     Abstract available


  329. MUPPIDI JR
    A role for NFAT signaling in ABC-DLBCL.
    Blood. 2020;135:81.
    PubMed    


  330. XIU Y, Dong Q, Fu L, Bossler A, et al
    Coactivation of NF-kappaB and Notch signaling is sufficient to induce B-cell transformation and enables B-myeloid conversion.
    Blood. 2020;135:108-120.
    PubMed     Abstract available


  331. ALDOSS I, Forman SJ
    How I Treat: Selecting CD19 Targeted Immunotherapies in Adult Patients with Advanced Acute Lymphoblastic Leukemia.
    Blood. 2020 Jan 3. pii: 430058. doi: 10.1182/blood.2019002132.
    PubMed     Abstract available


    December 2019
  332. ZHU H, Blum R, Bjordahl R, Gaidarova S, et al
    Pluripotent stem cell-derived NK cells with high-affinity non-cleavable CD16a mediate improved anti-tumor activity.
    Blood. 2019 Dec 19. pii: 429991. doi: 10.1182/blood.2019000621.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Malignant Lymphoma is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: